| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| SDF-1 | HOT GMP-SD1H13 | GMP Human SDF-1 / CXCL12 Protein | Human | E. coli | ![]() | MSSDS-PAGE | $720.00 50ug | ||
| SDF-1 | Human SDF-1 / CXCL12 Protein, premium grade | Human | E. coli | ![]() | HPLCSDS-PAGE | $360.00 50ug | |||
| SDF-1 | Human SDF-1 / CXCL12 Protein, Research Grade | Human | E. coli | ![]() | HPLCSDS-PAGE | $200.00 20ug | |||
| SDF-1 | Human SDF-1 / CXCL12 Protein, His Tag (HPLC & SPR verified) | Human | E. coli | ![]() | HPLCSDS-PAGE | $415.00 50ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Olaptesed Pegol | NOX-A12 | Phase 2 Clinical | Noxxon Pharma | Colorectal Neoplasms; Glioblastoma; Hematopoietic stem cell transplantation (HSCT); Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Pancreatic Neoplasms | Details |
| PTX-9908 | PTX-9908 | Phase 2 Clinical | Pertinax Therapeutics | Carcinoma, Hepatocellular | Details |
| JVS-100 | JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 | Phase 1 Clinical | Cleveland Clinic | Heart Failure; Ischemia; Peripheral Arterial Disease; Surgical Wound | Details |
| CK-0804 | CK-08041; CK-0804 | Phase 1 Clinical | Cellenkos Inc | Primary Myelofibrosis | Details |
| MyoCell SDF-1 | MyoCell SDF-1 | Clinical | U.S. Stem Cell | Heart Failure | Details |